Replies to post #589399 on NorthWest Biotherapeutics Inc (NWBO)

[Reefrad]

Bs. The presented their abstract in the earliest conference that was available. Had they waited for asco people would have complained that they waited too long. In any case the jama publication trumps everything so it’s no longer relevant.

[mike00h]

OncoJock, I see your point, but glioblastoma gets orphan treatment for being infrequent.
I think that's why we haven't gotten the podium at ASCO yet.

[skitahoe]

The truth is, once the data has been discussed elsewhere and in a journal, it is no longer acceptable at ASCO as it is not new information. If either the company or the clinicians had something that has never been presented, then an Abstract could be submitted and be likely to be accepted for presentation at ASCO or similar major conferences.

I don't know that Flaskworks has ever been presented, but I don't think ASCO is necessarily the best conference to present it at. New data on combination of DCVAX-L and other therapeutics could be presented, but they are trials that UCLA is running, not sponsored by NWBO, so I believe it is up to them when and where to present it. Let's see if anything shows up when the Abstracts are revealed.

Gary